Emerald Advisers Inc. PA reduced its holdings in AtriCure Inc. (NASDAQ:ATRC) by 1.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 553,411 shares of the medical device company’s stock after selling 7,290 shares during the quarter. Emerald Advisers Inc. PA owned approximately 1.61% of AtriCure worth $10,094,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. bought a new stake in shares of AtriCure in the 3rd quarter valued at $771,000. Skylands Capital LLC bought a new position in AtriCure during the fourth quarter worth $1,368,000. State Street Corp boosted its stake in AtriCure by 4.0% during the second quarter. State Street Corp now owns 617,405 shares of the medical device company’s stock worth $14,971,000 after acquiring an additional 23,790 shares in the last quarter. UBS Asset Management Americas Inc. acquired a new position in AtriCure during the second quarter worth $315,000. Finally, Vanguard Group Inc. raised its holdings in AtriCure by 3.8% during the second quarter. Vanguard Group Inc. now owns 1,446,732 shares of the medical device company’s stock worth $35,083,000 after buying an additional 52,761 shares during the last quarter. 86.36% of the stock is currently owned by institutional investors.
Several analysts have recently commented on ATRC shares. BidaskClub upgraded shares of AtriCure from a “strong sell” rating to a “sell” rating in a report on Thursday. Canaccord Genuity lowered their target price on shares of AtriCure from $28.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, November 2nd. Needham & Company LLC decreased their price objective on shares of AtriCure from $26.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, November 2nd. TheStreet downgraded shares of AtriCure from a “c-” rating to a “d+” rating in a report on Wednesday, November 29th. Finally, ValuEngine downgraded shares of AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $24.33.
AtriCure Inc. (NASDAQ:ATRC) opened at $16.72 on Thursday. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.28 and a quick ratio of 1.65. AtriCure Inc. has a 1 year low of $14.88 and a 1 year high of $25.18. The company has a market cap of $543.31, a P/E ratio of -16.39 and a beta of 0.39.
ILLEGAL ACTIVITY WARNING: This article was reported by Week Herald and is the property of of Week Herald. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://weekherald.com/2018/02/15/emerald-advisers-inc-pa-sells-7290-shares-of-atricure-inc-atrc.html.
AtriCure Company Profile
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.